Medical marijuana in the U.S. is at a crossroads as federal officials move to shift it from the tightly restricted Schedule I category toward Schedule III, following an executive order signed by President Donald Trump in December 2025 and a process begun under President Joe Biden in 2022. This change could ease research barriers and
Medical marijuana in the U.S. is at a crossroads as federal officials move to shift it from the tightly restricted Schedule I category toward Schedule III, following an executive order signed by President Donald Trump in December 2025 and a process begun under President Joe Biden in 2022. This change could ease research barriers and bring cannabis regulation more in line with its demonstrated medical uses, including FDA‑approved THC-based drugs for conditions like AIDS-related anorexia and chemotherapy-induced nausea.
Critics warn rescheduling may normalize a drug they link to serious health risks, while advocates argue marijuana is less addictive than many legal substances and should perhaps be removed from federal scheduling altogether. The debate now ranges from maintaining strict controls to full descheduling and decriminalization, with major implications for patients, doctors and law enforcement.
